Highly Processed Foods Could Be Addictive As Tobacco, Study Says
You might have heard the notion that processed foods are unhealthy, but that should
You might have heard the notion that processed foods are unhealthy, but that should
Often skin cancer is associated with exposure to ultraviolet light, but it turns out
Although most parents are concerned about the impact video games can have on their
A new research has shown that sleeping for less than five hours per night
A new study has established that strict parenting can lead to depression in children.
A new study has found that smoking cigarettes can block oestrogen production in women’s
Humans often sleep because they get to sleep, according to sleep researcher William Dement.
You may have heard that eating a balanced diet can reduce the risk for
According to new research, having dinner regularly as a family could be the key
According to the latest research, practicing mind relaxation techniques such as medication in older
Maintaining a healthy lifestyle is sometimes challenging, particularly if you’re constantly exposed to unhealthy
Exercise has numerous advantageous health effects in addition to aiding in weight loss or
This is partly because high-calorie food products are easy to find and cheap to buy. Finding suitable ways to prevent and treat obesity can make a huge difference in the length and quality of life for those who have it.
Treatments for Obesity such as the popular medication – Liraglutide, are giving severely overweight Americans renewed hope.
Phentermine/topiramate, naltrexone/bupropion, liraglutide, and semaglutide all seem to help people lose weight, and semaglutide may be the most effective of them all currently. This group of medicines just recently got the green light from the FDA. Though, it’s still very difficult to establish treatment guidelines because there aren’t enough long-term studies that look at how safe and effective obesity drugs are over time.
Patients who are dangerously obese still need weight-loss treatments, and the benefits of losing fat mass may be more important than the possible side effects of these medications. Clinicians are now being instructed to provide their patients whichever FDA-approved drug therapy they think will help them the most in their particular situation. Continue reading to compare the different treatments that the FDA recently approved to help people with severe weight problems, how they are given, and how they benefit obese people overall.
This is partly because high-calorie food products are easy to find and cheap to buy. Finding suitable ways to prevent and treat obesity can make a huge difference in the length and quality of life for those who have it.
Treatments for Obesity such as the popular medication – Liraglutide, are giving severely overweight Americans renewed hope.
Phentermine/topiramate, naltrexone/bupropion, liraglutide, and semaglutide all seem to help people lose weight, and semaglutide may be the most effective of them all currently. This group of medicines just recently got the green light from the FDA. Though, it’s still very difficult to establish treatment guidelines because there aren’t enough long-term studies that look at how safe and effective obesity drugs are over time.
Patients who are dangerously obese still need weight-loss treatments, and the benefits of losing fat mass may be more important than the possible side effects of these medications. Clinicians are now being instructed to provide their patients whichever FDA-approved drug therapy they think will help them the most in their particular situation. Continue reading to compare the different treatments that the FDA recently approved to help people with severe weight problems, how they are given, and how they benefit obese people overall.
In 1760, an English doctor named Malcolm Flemyng was the first person to call obesity a disease. Obesity has a bad reputation, but if it were seen as a disease instead of a social factor, the general public might change how they feel about it. Those who are overweight have a body mass index (BMI) of 25 or more, while those who are obese have a BMI of 30 or more. Obesity is a worldwide problem that is still getting worse. It affects billions of people all over the world.
WHO says that more than a billion people around the world are overweight, which puts them at greater risk of having their health get worse. Obesity has been linked to diabetes mellitus, heart disease, high blood pressure, stroke, less fertility in women, mental health problems, worse results from COVID-19, a higher risk of cancer, and ultimately a shorter life span.
Technology developments, a more sedentary lifestyle, and easier availability to high-calorie meals have all contributed to the rising incidence of obesity. Genetic factors are also significant. As a result, there are many different ways to treat obesity, including lifestyle changes, medication, and bariatric surgery. Additionally, pharmacotherapy might serve as a transitional measure between lifestyle changes and bariatric surgery.
A significantly large portion of the world’s population might have their quality of life enhanced by effective prevention and management, which could avert millions of deaths. For long-term weight reduction usage in 2022, the FDA has authorized five drugs: Orlistat, Phentermine-topiramate, Naltrexone-bupropion, Liraglutide, and Semaglutide. The latter of these medications is proving to be the more effective, long term, in the limited amount of studies that have been carried out on these medicines.
Semaglutide has been shown in studies to be significantly more effective for achieving and maintaining weight loss than the popular medication Liraglutide. The downside is the subcutaneous route of administration which might be inconvenient for some patients, although weekly dosing makes it a bit more convenient than daily subcutaneous dosing of Liraglutide.
Patients that can tolerate Semaglutide, find it can be added to behavioral therapy and diet modification for achieving and maintaining significant weight loss in the obese/overweight population. The possible superiority of Semaglutide with a similar risk of adverse effects makes it an excellent choice of drug for the management of obesity in the patient population that can take subcutaneous medication.
Semaglutide is administered subcutaneously in the abdomen, thighs, or upper arm. Use a new body region each time you administer an injection to yourself. Keep note of where each injection is administered to ensure a rotation of body locations. Examine the ink in the pen. It must be transparent and colorless. If it is hazy, discolored, or contains particles, do not use it.
Always use a fresh needle each time you inject medication, and never, under any circumstances, share injection pens. As sharing needles or pens might result in the spread of illness, it is unsafe for many individuals to use the same pen. Semaglutide must be injected weekly on the same day, at any time of day, with or without food.
Dosage instructions:
Brand name: Wegovy
Adults, At first, 0.25 milligrams (mg) injected under the skin once a week for 4 weeks. Your doctor may increase your dose every 4 weeks. However the dose is usually not more than 2.4 mg once a week.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-advertisement | 1 year | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
crumb | This cookie is set by websites that uses SquareSpace platform. The cookie is used to prevent cross-site request forgery (CSRF). | |
elementor | never | This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time. |
gdpr_status | 6 months 2 days | This cookie is set by the provider Media.net. This cookie is used to check the status whether the user has accepted the cookie consent box. It also helps in not showing the cookie consent box upon re-entry to the website. |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
XSRF-TOKEN | session | The cookie is set by Wix website building platform on Wix website. The cookie is used for security purposes. |
Cookie | Duration | Description |
---|---|---|
__gads | 1 year 24 days | This cookie is set by Google and stored under the name dounleclick.com. This cookie is used to track how many times users see a particular advert which helps in measuring the success of the campaign and calculate the revenue generated by the campaign. These cookies can only be read from the domain that it is set on so it will not track any data while browsing through another sites. |
_ga | 2 years | This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors. |
_ga_XZV5DHF9VD | 2 years | This cookie is installed by Google Analytics. |
_gat_gtag_UA_71463705_9 | 1 minute | This cookie is set by Google and is used to distinguish users. |
_gat_UA-71463705-9 | 1 minute | This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites. |
_gcl_au | 3 months | This cookie is used by Google Analytics to understand user interaction with the website. |
_gid | 1 day | This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form. |
CONSENT | 16 years 5 months 20 days 12 hours | These cookies are set via embedded youtube-videos. They register anonymous statistical data on for example how many times the video is displayed and what settings are used for playback.No sensitive data is collected unless you log in to your google account, in that case your choices are linked with your account, for example if you click “like” on a video. |
session_depth | 30 minutes | This cookie is used to store the number of pages a vistor visits in a session on the website. |
Cookie | Duration | Description |
---|---|---|
_fbp | 3 months | This cookie is set by Facebook to deliver advertisement when they are on Facebook or a digital platform powered by Facebook advertising after visiting this website. |
B | 1 year | This Cookie is used by Yahoo to provide ads, contents or analytics. |
DSID | 1 hour | This cookie is setup by doubleclick.net. This cookie is used by Google to make advertising more engaging to users and are stored under doubleclick.net. It contains an encrypted unique ID. |
fr | 3 months | The cookie is set by Facebook to show relevant advertisments to the users and measure and improve the advertisements. The cookie also tracks the behavior of the user across the web on sites that have Facebook pixel or Facebook social plugin. |
id | 1 year | The main purpose of this cookie is targeting and advertising. It is used to create a profile of the user's interest and to show relevant ads on their site. This Cookie is set by DoubleClick which is owned by Google. |
IDE | 1 year 24 days | Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile. |
test_cookie | 15 minutes | This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies. |
uuid2 | 3 months | This cookies is set by AppNexus. The cookies stores information that helps in distinguishing between devices and browsers. This information us used to select advertisements served by the platform and assess the performance of the advertisement and attribute payment for those advertisements. |
VISITOR_INFO1_LIVE | 5 months 27 days | This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website. |
YSC | session | This cookies is set by Youtube and is used to track the views of embedded videos. |
Cookie | Duration | Description |
---|---|---|
__ib2pgses_1186_a | session | No description |
__ib2pgses_1198_a | session | No description |
__ib2pgses_1221_a | session | No description |
__ib2pgses_1253_a | session | No description |
__ib2pgses_1283_a | session | No description |
__ib2pgses_1476_a | session | No description |
__ib2vid | 1 month | No description available. |
_app_session | 1 month | No description available. |
_gfpc | session | No description available. |
A3 | 1 year | No description |
akacd_widgets_routing | past | No description available. |
ans3 | 2 days | No description |
check | 1 day | No description available. |
GoogleAdServingTest | session | No description |
L-y13n2 | 1 day | No description |
outbrain_cid_fetch | 5 minutes | No description available. |
owner_token | 1 day | No description available. |
PP-y13n2 | 1 hour | No description |
r | 7 days | No description |
recs_3e571bd1fd579a0c57cc16aa155ba54b | past | No description |
RL-y13n2 | 1 day | No description |
thirdparty | 1 hour | No description available. |
yt-remote-connected-devices | never | No description available. |
yt-remote-device-id | never | No description available. |